Indaptus Therapeutics is trading 6.52% higher at $4.25, after closing September 22, 2026 at $3.99, with broader biotechnology-sector strength supporting sentiment; no new company-specific announcement or major catalyst was identified for September 23. - XBI was up 2.61% pre-market. - The stock follows a highly volatile week. - The earlier $24 million private placement, announced September 8, remains a potentially relevant backdrop.